Results 1 to 10 of about 3,046 (215)

Evidence-Based Nursing Management During Mavacamten Therapy in an 89-Year-Old Patient With Symptomatic Hypertrophic Obstructive Cardiomyopathy: A Case Report. [PDF]

Clin Case Rep
ABSTRACT In older patients receiving mavacamten, a reduction in NT‐proBNP levels may coexist with persistent severe LVOTO. Nurses should interpret this biomarker–echocardiography discordance as a safety signal and maintain structured cardiovascular surveillance rather than assuming treatment success based solely on biomarker improvement.
Wang F.
europepmc   +2 more sources

Dynamic LVOT Obstruction After Mitral Valve Repair in HCM: Treatment With a Cardiac Myosin Inhibitor. [PDF]

JACC Case Rep
Gabr EM, Vignarajah A, Shah G.
europepmc   +1 more source

Mavacamten's Dose-Time Dynamics and Predictive Factors in Hypertrophic Obstructive Cardiomyopathy Cardiac Remodeling. [PDF]

Echocardiography
Cao B, Li Y, Chen X.
europepmc   +1 more source

Mavacamten in adolescent obstructive hypertrophic cardiomyopathy: SCOUTing a way forward. [PDF]

Heart Fail Rev
Bennetts JD, Ngo DTM, Cheema B, Hosseini K, Verheyen N, Santner V, Tomasoni D, Sverdlov AL.   +7 more
europepmc   +1 more source

Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM. [PDF]

Eur Cardiol
Hasegawa K, Iguchi M, Wada H, Dan GA.
europepmc   +1 more source

Evaluation of the effect of mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work. [PDF]

Clin Physiol Funct Imaging
Wan L, Chen X, Huang Z, Ren J, Lu W, Ran H.   +5 more
europepmc   +1 more source

Mavacamten toxicity, hepatic dysfunction, and rifampicin: cause or coincidence? [PDF]

Eur Heart J Case Rep
Mapelli M, Costantino S, Maragna R.
europepmc   +1 more source

Fabry cardiomyopathy presenting as hypertrophic phenotype with left ventricular outflow tract obstruction: a case series. [PDF]

Front Cardiovasc Med
Hosyanto FF, Li Y, Luo S, Huang B.
europepmc   +1 more source

Coexistence of Hypertrophic Cardiomyopathy and Hereditary Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Case Rep
Coderre R, Tersalvi G, Adigun RO, Boilson BA, Borgeson DD, Clavell AL, Chang IC, Dispenzieri A, Grogan M, AbouEzzeddine OF.   +9 more
europepmc   +1 more source

Mavacamten in Symptomatic Hypertrophic Cardiomyopathy

JACC: Asia
Chung-Lieh Hung, Yen-Wen Liu, Yen-Wen Wu
openaire   +2 more sources